FDA approves new larger production setup for Genmab drug
After the US health authorities approved a new production setup at Horizon Therapeutics, which holds the rights to Genmab's drug Tepezza, the company expects that current supply-related issues will soon be resolved.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
With April 1 as the starting point, Horizon Therapeutics expects to put a stop to the supply issues which have affected the company's new and highly popular launch Tepezza since December last year, which the firm states in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
